Compare iShares Global Tech ETF (IXN) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Tech ETF vs Revvity Inc — how do they compare? iShares Global Tech ETF trades at $149.75 (market cap $10.03B), while Revvity Inc trades at $154.34 (market cap $16.98B). The key difference: Revvity Inc is the larger of the two by market cap, and Revvity Inc pays a 0.18% dividend while iShares Global Tech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Tech ETF for 47 Days and Revvity Inc for 12 Days on average.
| IXN | RVTY | |
|---|---|---|
Market Cap | $10.03B | $16.98B |
Volume | 286,617 | 1,456,900 |
Sector | Sector/Thematic | Health |
52-Week High | $152.94 | $157.36 |
52-Week Low | $95.76 | $82.26 |
Typical Hold Time | 47 Days | 12 Days |
Enterprise Value | — | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IXN trades at $152.16, down 0.51% today but near its 52-week high of $151.40, reflecting strong momentum. Technical indicators show a bullish moving average signal but overbought RSI levels. Recent news highlights the ETF's 34% gain and multiple compression, with a high-teens P/E ratio and 28.5% long-term EPS growth rate, emphasizing global tech exposure beyond the U.S.
The outlook remains positive due to AI exposure and global diversification, but risks include portfolio concentration and overbought conditions. Analyst sentiment is bullish, with buy ratings citing valuation appeal, though investors should monitor tech sector volatility and competitive pressures from international firms.
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Global Tech ETF
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
